BioVie (BIVI) Registration filing summary

Company overview and business model

• Focuses on developing innovative drug therapies for neurological, neurodegenerative disorders, and advanced liver disease.

• Lead asset bezisterim (NE3107) targets inflammation-driven insulin resistance, with programs in Alzheimer's, Parkinson's, and long COVID.

• Liver program BIV201 (terlipressin) targets ascites in cirrhosis, with FDA Fast Track and Orphan Drug status.

Financial performance and metrics

• As of June 30, 2026, cash and cash equivalents were $10.3M (actual), $14.3M (as adjusted), and $33.0M (as further adjusted for the offering).

• Accumulated deficit stands at $374.3M, with total stockholders' equity at $34.3M (as further adjusted).

• Net tangible book value per share post-offering is estimated at $1.39, with immediate dilution of $0.17 per share to new investors.

Use of proceeds and capital allocation

• Estimated net proceeds of $22.7M (assuming full sale at $1.56 per share), with no minimum offering amount.

• Proceeds intended for working capital, general corporate purposes, capital expenditures, R&D, and potential acquisitions.

• Management has broad discretion over allocation of funds.